Streetbeat News

Revenues

CVE

Cenovus Energy (NYSE:CVE) reported Q2 earnings per share of $0.39, missing the analyst estimate of $0.52 by 25%. However, the company reported sales of $10.89 billion, beating the estimate of $10.56 billion by 3.13%.

Portfolio Pulse from totan@benzinga.com

August 01, 2024 | 10:21 am

RSI

Rush Street Interactive shares are trading higher after the company reported better-than-expected Q2 earnings and raised its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:20 am

PRM

Perimeter Solutions (NYSE:PRM) reported Q2 2024 GAAP EPS of $0.14, a 54.84% decrease from $0.31 YoY. However, sales were $127.276M, beating the $87.520M estimate and showing a 67.17% increase YoY.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:18 am

CAMT

Camtek expects Q3 2024 revenue between $107M-$110M, surpassing estimates of $104.014M. This represents a 35% mid-point increase over Q3 2023. Management anticipates continued sequential growth into Q4 due to strong order flow.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:18 am

CWEN

Clearway Energy (NYSE:CWEN) reported Q2 earnings per share (EPS) of $0.43, a 30.3% increase from $0.33 YoY. However, sales decreased by 9.85% to $366 million from $406 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:17 am

CI

Cigna has reaffirmed its fiscal year 2024 adjusted revenues of at least $235 billion, which is slightly below the consensus estimate of $235.51 billion. The company also provided an adjusted EPS guidance of at least $28.40, compared to the consensus of $28.50.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:17 am

XEL

Xcel Energy has affirmed its FY24 adjusted EPS guidance of $3.50-$3.60, aligning closely with the $3.56 estimate. Key assumptions include constructive outcomes in rate cases, normal weather patterns, and a slight increase in weather-normalized retail electric sales. O&M expenses and interest expenses are projected to rise, while property taxes remain flat.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:13 am

PAX

Patria Investments (NASDAQ:PAX) reported Q2 2024 earnings per share of $0.22, meeting analyst expectations, and sales of $70.2 million, beating estimates by 1.88%. Despite a 24.14% decrease in EPS from last year, sales increased by 13.96%.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:13 am

OCSL

Oaktree Specialty Lending (NASDAQ:OCSL) reported Q3 2024 earnings per share of $0.55, missing the analyst estimate of $0.56. The company also reported sales of $94.966 million, falling short of the $99.380 million estimate and representing a 6.80% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:13 am

TIL

Instil Bio and ImmuneOnco have entered into a license and collaboration agreement. Instil Bio will in-license ex-China development and commercial rights to ImmuneOnco's PD-L1xVEGF bispecific antibody, IMM2510, and next-generation anti-CTLA-4 antibody, IMM27M. ImmuneOnco will receive an upfront payment, potential near-term payments up to $50 million, and potential milestones exceeding $2 billion.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:12 am